tilsotolimod
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for tilsotolimod, covering 2022-02-17 to 2024-10-18. Get the full timeline:
Most recent: Clinical Trial Update: Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers [Phase 1]